ClinicalTrials.gg
Not yet recruitingNCT07643584DEMANDUpdated Oct 16, 2026

De-Escalation of Axillary Management in Advanced Nodal Disease

A Phase 2 interventional study of Axillary Surgery in Breast Cancer, sponsored by University of Kansas Medical Center. Not yet recruiting. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-10-16.

Sponsored by University of Kansas Medical Center · Phase 2, Interventional, and Treatment

How we know

Updated Oct 16, 2026Start date movedPrimary completion moved+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
120
Allocation
Not applicable
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 31 studies in Breast Neoplasms by University of Kansas Medical Center — 6 open to participants now, 14 under way, none of them phase 3. Breast Neoplasms · University of Kansas Medical Center.

Planned enrollment
7th of 28
120 · median 71
Started
2026
with 1 other
Phase 2
16 of 31
3 open now
Primary completion
2031-10
later than 12 of 13 live
Registered
30th of 31
by date

Among the 31 studies in Breast Neoplasms by University of Kansas Medical Center, this one is the 7th largest by planned enrollment of the 28 interventional ones that give a count, is one of 2 that started in 2026, is one of 16 in phase 2, reaches primary completion later than 12 of the 13 other live ones, and was the 30th registered.

Breast Neoplasms

14,855 studies on the registry are indexed under Breast Neoplasms; 3,321 are open to participants now.

Browse Breast Neoplasms studies →

Open to participants now

6 of the 31 studies in Breast Neoplasms by University of Kansas Medical Center are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 6 open studies →

Where they have run

Who these studies take

Of the 2,403 Breast Neoplasms studies recruiting now, 1,574 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 215 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 31 studies in Breast Neoplasms by University of Kansas Medical Center, or all of them as a file.
02

Study summary

This is a prospective, phase 2, single arm trial to evaluate whether Axillary Lymph Node Dissection (ALND) can be safely omitted for patients with cN2 and cN3 breast cancer who achieve a complete clinical response on exam with a complete or partial response by end-of-treatment (EOT) imaging and have either a partial or complete pathologic nodal response after neoadjuvant chemotherapy (NAC) by performing nodal assessment of sentinel lymph node surgery (with or without targeted axillary dissection (TAD) followed by Regional Nodal Irradiation (RNI).

This study aims to demonstrate that performing only a sentinel node dissection, which includes the removal of palpably gross disease followed by radiation, will not impact distant disease and thus survival.

03

Conditions studied

  • Breast Cancer

Browse trials for

04

Who can participate

The criteria were revised on the registry on Oct 16, 2026. See what changed

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Ability of participant to understand this study, and participant willingness to sign a written . NOTE Remote consenting allowed per IRB policy and approval.
  2. Stated willingness to comply with all study procedures and lifestyle considerations and availability for the duration of the study
  3. Males and/or females age ≥ 18 to 80 years
  4. Clinical stage T1-3 N2-3 M0 breast cancer at diagnosis (prior to the start of chemotherapy).
  5. All patients must have had an axillary ultrasound with FNA or core needle of axillary lymph nodes documenting axillary at the time of diagnosis, prior to or at most 14 days after starting neoadjuvant chemotherapy.
  6. Patients must have had estrogen receptor, progesterone receptor and status (by IHC and/or ISH) evaluated on diagnostic core biopsy prior to start of neoadjuvant chemotherapy. Note: If HER2 status has not been clearly determined (i.e. equivocal/indeterminate), then patients should not be enrolled (see exclusion criteria).
  7. Patients must have completed planned chemotherapy (neoadjuvant chemotherapy [NAC]) prior to surgery. Sandwich chemotherapy is not allowed (i.e. chemotherapy planned to be given after surgery). Adjuvant systemic therapy based on final surgical pathology is allowed and at the discretion of the treating medical oncologist. Note: Delays/dose modifications due to toxicities/adverse events are allowed per the treating medical oncologist.
  8. Patients with HER-2 positive tumors must have received neoadjuvant trastuzumab, or trastuzumab + pertuzumab, or other approved anti-HER-2 therapy (either with all or with a portion of the neoadjuvant chemotherapy regimen). Therapy must be FDA-approved targeted anti-HER2 therapy, but additional therapies are allowed as are non-trastuzumab regimens if administered in the context of an IRB-approved clinical trial.
  9. Benign breast disease, LCIS or DCIS of contralateral breast is allowed
  10. All patients must have a clinically negative axilla (no bulky adenopathy) on physical examination documented at the completion of neoadjuvant chemotherapy. Note: A partial or complete imaging response that includes all lymph nodes measuring ≤ 1cm clinically is required for eligibility.
  11. (Zubrod) Performance Status 0-1 (Appendix A)
  12. Breast surgery (lumpectomy or mastectomy) and sentinel lymph node surgery must be completed within 56 days of the completion of the last dose of neoadjuvant chemotherapy. Negative margin (by either breast conservation or mastectomy) on final pathology where negative margin is defined as no tumor on ink.
  13. Females of must have a negative serum pregnancy test performed - according to institutional standard of care prior to surgery.
  14. Females of child-bearing potential and males with partners of child-bearing potential must agree not to donate sperm, to practice sexual abstinence or to use the forms of listed in Child-Bearing Potential/Pregnancy section for the duration of study participation and, following the last administration of therapy , for as long as directed per standard or care chemotherapy ( regimen allowed) and radiation therapy, whichever is longer. Note: Peri-menopausal women must be amenorrheic for ≥ 12 months to be considered not of childbearing potential.

Definition of medically fit for surgery:

  • ECOG status of 0-1
  • NOTE - participants are eligible for surgery if they have nicotine in the blood or high A1c. These values will be monitored per SOC.

Exclusion criteria

Exclusion Criteria:

  1. Diagnosed with a psychiatric illness or is in a social situation that would limit compliance with study requirements and / or giving .
  2. Medical condition such as uncontrolled infection (including ), uncontrolled diabetes mellitus or cardiac disease which, in the opinion of the treating physician, would make this study unreasonably hazardous for the patient.
  3. Inflammatory breast cancer.
  4. Any other within 5 years of enrollment with the exception of basal cell or squamous cell carcinoma of the skin treated with local resection only or carcinoma in situ of the cervix.
  5. status has not been clearly determined (i.e. equivocal/indeterminate)
  6. Patient has had endocrine therapy > than 8 weeks prior to the start of neoadjuvant chemotherapy.
  7. Neoadjuvant radiation therapy.
  8. SLN surgery/excisional for pathological confirmation of axillary status prior to or during neoadjuvant chemotherapy.
  9. Prior history of ipsilateral breast cancer (invasive disease or DCIS). NOTE LCIS and benign breast disease is allowed.
  10. Prior ipsilateral axillary surgery, such as excisional biopsy of lymph node(s) or treatment of hidradenitis.
  11. History of prior or concurrent contralateral invasive breast cancer. .
  12. Patient pregnant or nursing.
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

HER2

HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.

In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
120 participants (estimated)

Study arms

  • Experimental
    Axillary Surgery

    Procedure: Axillary Surgery

Interventions

  • ProcedureAxillary Surgery

    Patients who are clinically node negative after neoadjuvant chemotherapy by physical examination will undergo clinically indicated breast surgery (mastectomy or lumpectomy) with sentinel lymph node (SLN) surgery. Sentinel lymph node surgery must be performed within 8 weeks (56 days) after completion of the last dose of neoadjuvant chemotherapy.

06

What researchers measure

Primary outcomes

  1. Disease Free Survival (DFS)

    To determine if radiation to the undissected axilla and regional lymph nodes is not inferior to axillary lymph node dissection with regional nodal irradiation (excluding dissected axilla) for DFS after neoadjuvant chemotherapy response. DFS assessed according to National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) v6.0.

    Time frame: 5 years

Secondary outcomes

  1. Invasive Breast Cancer Recurrence Free Interval (IBC - RFI)

    To assess if radiation to the undissected axilla and regional nodes is not inferior to axillary dissection plus regional nodal radiation for IBC-RFI, DSS, and LRR in patients with complete or partial response to neoadjuvant chemotherapy. Determined by medical record.

    Time frame: 5 years

  2. Disease Specific Survival (DSS)

    To assess if radiation to the undissected axilla and regional nodes is not inferior to axillary dissection plus regional nodal radiation for IBC-RFI, DSS, and LRR in patients with complete or partial response to neoadjuvant chemotherapy. Determined by medical record.

    Time frame: 5 years

  3. Locoregional Recurrence (LRR)

    To assess if radiation to the undissected axilla and regional nodes is not inferior to axillary dissection plus regional nodal radiation for IBC-RFI, DSS, and LRR in patients with complete or partial response to neoadjuvant chemotherapy. Determined by medical record.

    Time frame: 5 years

  4. Lymphedema Incidence

    To estimate the incidence of arm lymphedema in participants that undergo SLN with comprehensive RNI. Determined by Bioimpedance Spectroscopy

    Time frame: Measured at 9 months, annually, and PRN (as needed) per patient reported symptoms, over a duration of approximately 5 years.

  5. Recurrence Cancer Burden (RCB) Score

    To estimate the distribution or Recurrence Cancer Burden (RCB) Score

    Time frame: Measured at final surgical pathology (up to 21 days after surgery)

  6. Imaging positive predictive value for extent of nodal disease burden compared to final surgical pathology and lab draws

    Assessed by MRI, US, and final surgical pathology. The same imaging modality used to assess nodal adenopathy at baseline must be used throughout. RECIST v 1.1 criteria will be used for assessments.

    Time frame: Measured at final surgical pathology (up to 21 days after surgery)

Other outcomes

  1. ctDNA Analysis

    To evaluate ctDNA following neoadjuvant chemotherapy in participants with locally advanced breast cancer

    Time frame: ctDNA will be collected prior to start of neoadjuvant chemotherapy, day of surgery, and within 30 days of completing radiation therapy

07

Study locations

No study locations are listed for this record.

08

References and documents

Publications

  • Kim EJ, Yoo TK, Kim J, Chung IY, Ko BS, Kim HJ, Lee JW, Son BH, Lee SB. Feasibility of de-escalating axillary surgery in patients with clinical N2-3, pathological N0 breast cancer after neoadjuvant chemotherapy. Sci Rep. 2025 Apr 1;15(1):11128. doi: 10.1038/s41598-024-84841-y. PubMed 40169643 ↗
  • Cabioglu N, Kocer HB, Karanlik H, Gulcelik MA, Igci A, Muslumanoglu M, Uras C, Mantoglu B, Trabulus DC, Akgul G, Tukenmez M, Senol K, Ozkurt E, Sen E, Karadeniz Cakmak G, Bademler S, Emiroglu S, Yildirim N, Kara H, Dag A, Dilege E, Altinok A, Basaran G, Varol E, Ugurlu U, Bolukbasi Y, Ersoy YE, Zengel B, Karaman N, Ozbas S, Zer L, Gul Kilic H, Agcaoglu O, Sakman G, Utkan Z, Soyder A, Akcan A, Ergun S, Yilmaz R, Aydiner A, Soran A, Ibis K, Ozmen V. De-Escalation of Nodal Surgery in Clinically Node-Positive Breast Cancer. JAMA Surg. 2025 Mar 1;160(3):257-266. doi: 10.1001/jamasurg.2024.5913. PubMed 39745737 ↗
  • Muslumanoglu M, Cabioglu N, Igci A, Karanlik H, Kocer HB, Senol K, Mantoglu B, Tukenmez M, Cakmak GK, Ozkurt E, Gulcelik MA, Emiroglu S, Mollavelioglu B, Yildirim N, Bademler S, Zengel B, Trabulus DC, Ugurlu MU, Uras C, Ilgun S, Akgul GG, Akcan A, Yormaz S, Ersoy YE, Ozbas S, Dilege E, Citgez B, Bolukbasi Y, Altinok A, Dag A, Basaran G, Utkan NZ, Ozcinar B, Arici C, AlJorani I, Kara H, Yigit B, Sen E, Erozgen F, Soyder A, Celik B, Kilic HG, Zer L, Sakman G, Yeniay L, Atahan K, Varol E, Veliyeva V, Goktepe B, Velidedeoglu M, Karaman N, Soran A, Aydiner A, Yilmaz R, Ibis K, Ozmen V. Combined analysis of the MF18-02/MF18-03 NEOSENTITURK studies: ypN-positive disease does not necessitate axillary lymph node dissection in patients with breast cancer with a good response to neoadjuvant chemotherapy as long as radiotherapy is provided. Cancer. 2025 Jan 1;131(1):e35610. doi: 10.1002/cncr.35610. Epub 2024 Oct 30. PubMed 39476303 ↗
  • Vega, R M, Deladisma AM, Mobley E M, et al., Axillary surgery efficacy for patients with breast cancer receiving neoadjuvant chemotherapy on NSABP B40 and B41. 2023, Journal of Clinical Oncology: J Clin Oncol 41, 2023 (suppl 16; abstr 524).
  • Montagna G, Mrdutt MM, Sun SX, Hlavin C, Diego EJ, Wong SM, Barrio AV, van den Bruele AB, Cabioglu N, Sevilimedu V, Rosenberger LH, Hwang ES, Ingham A, Papassotiropoulos B, Nguyen-Strauli BD, Kurzeder C, Aybar DD, Vorburger D, Matlac DM, Ostapenko E, Riedel F, Fitzal F, Meani F, Fick F, Sagasser J, Heil J, Karanlik H, Dedes KJ, Romics L, Banys-Paluchowski M, Muslumanoglu M, Perez MDRC, Diaz MC, Heidinger M, Fehr MK, Reinisch M, Tukenmez M, Maggi N, Rocco N, Ditsch N, Gentilini OD, Paulinelli RR, Zarhi SS, Kuemmel S, Bruzas S, di Lascio S, Parissenti TK, Hoskin TL, Guth U, Ovalle V, Tausch C, Kuerer HM, Caudle AS, Boileau JF, Boughey JC, Kuhn T, Morrow M, Weber WP. Omission of Axillary Dissection Following Nodal Downstaging With Neoadjuvant Chemotherapy. JAMA Oncol. 2024 Jun 1;10(6):793-798. doi: 10.1001/jamaoncol.2024.0578. PubMed 38662396 ↗
  • Brackstone M, Baldassarre FG, Perera FE, Cil T, Chavez Mac Gregor M, Dayes IS, Engel J, Horton JK, King TA, Kornecki A, George R, SenGupta SK, Spears PA, Eisen AF. Management of the Axilla in Early-Stage Breast Cancer: Ontario Health (Cancer Care Ontario) and ASCO Guideline. J Clin Oncol. 2021 Sep 20;39(27):3056-3082. doi: 10.1200/JCO.21.00934. Epub 2021 Jul 19. PubMed 34279999 ↗
  • Cabioglu N, Karanlik H, Yildirim N, Muslumanoglu M, Cakmak Karadeniz G, Trabulus Can D, Tukenmez M, Ersoy YE, Uras C, Zengel B, Emiroglu S, Polat AK, Yeniay L, Ozkurt E, Kara H, Ibis K, Aydiner A, Ozmen V, Igci A. Favorable outcome with sentinel lymph node biopsy alone after neoadjuvant chemotherapy in clinically node positive breast cancer at diagnosis: Turkish Multicentric NEOSENTI-TURK MF-18-02-study. Eur J Surg Oncol. 2021 Oct;47(10):2506-2514. doi: 10.1016/j.ejso.2021.06.024. Epub 2021 Jun 24. PubMed 34217580 ↗
  • Pilewskie M, Morrow M. Axillary Nodal Management Following Neoadjuvant Chemotherapy: A Review. JAMA Oncol. 2017 Apr 1;3(4):549-555. doi: 10.1001/jamaoncol.2016.4163. PubMed 27918753 ↗
  • Recht A, Comen EA, Fine RE, Fleming GF, Hardenbergh PH, Ho AY, Hudis CA, Hwang ES, Kirshner JJ, Morrow M, Salerno KE, Sledge GW Jr, Solin LJ, Spears PA, Whelan TJ, Somerfield MR, Edge SB. Postmastectomy Radiotherapy: An American Society of Clinical Oncology, American Society for Radiation Oncology, and Society of Surgical Oncology Focused Guideline Update. Pract Radiat Oncol. 2016 Nov-Dec;6(6):e219-e234. doi: 10.1016/j.prro.2016.08.009. Epub 2016 Sep 19. PubMed 27659727 ↗
  • Huang EH, Tucker SL, Strom EA, McNeese MD, Kuerer HM, Hortobagyi GN, Buzdar AU, Valero V, Perkins GH, Schechter NR, Hunt KK, Sahin AA, Buchholz TA. Predictors of locoregional recurrence in patients with locally advanced breast cancer treated with neoadjuvant chemotherapy, mastectomy, and radiotherapy. Int J Radiat Oncol Biol Phys. 2005 Jun 1;62(2):351-7. doi: 10.1016/j.ijrobp.2004.09.056. PubMed 15890574 ↗
  • Mamounas EP. Impact of neoadjuvant chemotherapy on locoregional surgical treatment of breast cancer. Ann Surg Oncol. 2015 May;22(5):1425-33. doi: 10.1245/s10434-015-4406-6. Epub 2015 Mar 2. PubMed 25727558 ↗
  • Gerber B, Schneeweiss A, Mobus V, Golatta M, Tesch H, Krug D, Hanusch C, Denkert C, Lubbe K, Heil J, Huober J, Ataseven B, Klare P, Hahn M, Untch M, Kast K, Jackisch C, Thomalla J, Seither F, Blohmer JU, Rhiem K, Fasching PA, Nekljudova V, Loibl S, Kuhn T. Pathological Response in the Breast and Axillary Lymph Nodes after Neoadjuvant Systemic Treatment in Patients with Initially Node-Positive Breast Cancer Correlates with Disease Free Survival: An Exploratory Analysis of the GeparOcto Trial. Cancers (Basel). 2022 Jan 20;14(3):521. doi: 10.3390/cancers14030521. PubMed 35158789 ↗
  • Guo L, Xie G, Wang R, Yang L, Sun L, Xu M, Yang W, Chung MC. Local treatment for triple-negative breast cancer patients undergoing chemotherapy: breast-conserving surgery or total mastectomy? BMC Cancer. 2021 Jun 19;21(1):717. doi: 10.1186/s12885-021-08429-9. PubMed 34147061 ↗
  • Kuemmel S, Heil J, Bruzas S, Breit E, Schindowski D, Harrach H, Chiari O, Hellerhoff K, Bensmann E, Hanf V, Grasshoff ST, Deuschle P, Belke K, Polata S, Paepke S, Warm M, Meiler J, Schindlbeck C, Ruhwedel W, Beckmann U, Groh U, Dall P, Blohmer JU, Traut A, Reinisch M. Safety of Targeted Axillary Dissection After Neoadjuvant Therapy in Patients With Node-Positive Breast Cancer. JAMA Surg. 2023 Aug 1;158(8):807-815. doi: 10.1001/jamasurg.2023.1772. PubMed 37285140 ↗
  • Mamounas EP, Bandos H, White JR, Julian TB, Khan AJ, Shaitelman SF, Torres MA, Vicini FA, Ganz PA, McCloskey SA, Lucas PC, Gupta N, Li XA, McCormick B, Smith B, Tendulkar RD, Kavadi VS, Matsumoto K, Seaward SA, Irvin WJ Jr, Lin JY, Mutter RW, Muanza TM, Stromberg J, Jagsi R, Weiss AC, Curran WJ Jr, Wolmark N. Omitting Regional Nodal Irradiation after Response to Neoadjuvant Chemotherapy. N Engl J Med. 2025 Jun 5;392(21):2113-2124. doi: 10.1056/NEJMoa2414859. PubMed 40466065 ↗
  • Korde LA, Somerfield MR, Carey LA, Crews JR, Denduluri N, Hwang ES, Khan SA, Loibl S, Morris EA, Perez A, Regan MM, Spears PA, Sudheendra PK, Symmans WF, Yung RL, Harvey BE, Hershman DL. Neoadjuvant Chemotherapy, Endocrine Therapy, and Targeted Therapy for Breast Cancer: ASCO Guideline. J Clin Oncol. 2021 May 1;39(13):1485-1505. doi: 10.1200/JCO.20.03399. Epub 2021 Jan 28. PubMed 33507815 ↗
  • Shin E, Yoo TK, Kim J, Chung IY, Ko BS, Kim HJ, Lee JW, Son BH, Lee SB. Evaluating the survival outcomes in clinical node stage 2 and 3 breast cancer patients with negative sentinel lymph node biopsy after neoadjuvant chemotherapy: sentinel lymph node biopsy alone vs. axillary lymph node dissection. Front Oncol. 2025 May 20;15:1563586. doi: 10.3389/fonc.2025.1563586. eCollection 2025. PubMed 40463878 ↗
  • Jagsi R, Barlow WE, Woodward WA, Connolly E, Mahtani R, Shumway D, Speers C, Stecklein SR, Zeidan Y, Zhang H, Sharma P, Pusztai L, Hortobagyi GN, Kalinsky K. Radiotherapy Use and Incidence of Locoregional Recurrence in Patients With Favorable-Risk, Node-Positive Breast Cancer Enrolled in the SWOG S1007 Trial. JAMA Oncol. 2023 Aug 1;9(8):1083-1089. doi: 10.1001/jamaoncol.2023.1984. PubMed 37410451 ↗
  • Andring LM, Diao K, Sun S, Patel M, Whitman GJ, Schlembach P, Arzu I, Joyner MM, Shaitelman SF, Hoffman K, Stauder MC, Smith BD, Woodward WA. Locoregional Management and Prognostic Factors in Breast Cancer With Ipsilateral Internal Mammary and Axillary Lymph Node Involvement. Int J Radiat Oncol Biol Phys. 2022 Jul 1;113(3):552-560. doi: 10.1016/j.ijrobp.2022.02.037. Epub 2022 Mar 4. PubMed 35248602 ↗
  • Park HJ, Shin KH, Cho KH, Park IH, Lee KS, Ro J, Jung SY, Lee S, Kim SW, Kang HS, Chie EK, Ha SW. Outcomes of positron emission tomography-staged clinical N3 breast cancer treated with neoadjuvant chemotherapy, surgery, and radiotherapy. Int J Radiat Oncol Biol Phys. 2011 Dec 1;81(5):e689-95. doi: 10.1016/j.ijrobp.2010.11.061. Epub 2011 Feb 6. PubMed 21300467 ↗
  • Mamounas EP, Brown A, Anderson S, Smith R, Julian T, Miller B, Bear HD, Caldwell CB, Walker AP, Mikkelson WM, Stauffer JS, Robidoux A, Theoret H, Soran A, Fisher B, Wickerham DL, Wolmark N. Sentinel node biopsy after neoadjuvant chemotherapy in breast cancer: results from National Surgical Adjuvant Breast and Bowel Project Protocol B-27. J Clin Oncol. 2005 Apr 20;23(12):2694-702. doi: 10.1200/JCO.2005.05.188. PubMed 15837984 ↗
  • Boughey JC, Suman VJ, Mittendorf EA, Ahrendt GM, Wilke LG, Taback B, Leitch AM, Flippo-Morton TS, Kuerer HM, Bowling M, Hunt KK; Alliance for Clinical Trials in Oncology. Factors affecting sentinel lymph node identification rate after neoadjuvant chemotherapy for breast cancer patients enrolled in ACOSOG Z1071 (Alliance). Ann Surg. 2015 Mar;261(3):547-52. doi: 10.1097/SLA.0000000000000551. PubMed 25664534 ↗
  • Che Bakri NA, Kwasnicki RM, Khan N, Ghandour O, Lee A, Grant Y, Dawidziuk A, Darzi A, Ashrafian H, Leff DR. Impact of Axillary Lymph Node Dissection and Sentinel Lymph Node Biopsy on Upper Limb Morbidity in Breast Cancer Patients: A Systematic Review and Meta-Analysis. Ann Surg. 2023 Apr 1;277(4):572-580. doi: 10.1097/SLA.0000000000005671. Epub 2022 Aug 10. PubMed 35946806 ↗
  • Zhang JQ, Montagna G, Sevilimedu V, Abbate K, Charyn J, Mehrara B, Morrow M, Barrio AV. Longitudinal Prospective Evaluation of Quality of Life After Axillary Lymph Node Dissection. Ann Surg Oncol. 2022 Apr 1:10.1245/s10434-022-11623-z. doi: 10.1245/s10434-022-11623-z. Online ahead of print. PubMed 35364766 ↗
  • Appelgren M, Sackey H, Wengstrom Y, Johansson K, Ahlgren J, Andersson Y, Bergkvist L, Frisell J, Lundstedt D, Ryden L, Sund M, Alkner S, Vrou Offersen B, Filtenborg Tvedskov T, Christiansen P, de Boniface J; SENOMAC Trialists' Group. Patient-reported outcomes one year after positive sentinel lymph node biopsy with or without axillary lymph node dissection in the randomized SENOMAC trial. Breast. 2022 Jun;63:16-23. doi: 10.1016/j.breast.2022.02.013. Epub 2022 Mar 1. PubMed 35279508 ↗
  • Vrancken Peeters NJMC, Kaplan ZLR, Clarijs ME, Mureau MAM, Verhoef C, van Dalen T, Husson O, Koppert LB. Health-related quality of life (HRQoL) after different axillary treatments in women with breast cancer: a 1-year longitudinal cohort study. Qual Life Res. 2024 Feb;33(2):467-479. doi: 10.1007/s11136-023-03538-3. Epub 2023 Oct 27. PubMed 37889384 ↗
  • Tarkowska M, Glowacka-Mrotek I, Nowikiewicz T, Goch A, Zegarski W. Quality of Life in Women Subjected to Surgical Treatment of Breast Cancer Depending on the Procedure Performed within the Breast and Axillary Fossa-A Single-Center, One Year Prospective Analysis. J Clin Med. 2021 Mar 24;10(7):1339. doi: 10.3390/jcm10071339. PubMed 33804935 ↗
  • Kilgore LJ, Korentager SS, Hangge AN, Amin AL, Balanoff CR, Larson KE, Mitchell MP, Chen JG, Burgen E, Khan QJ, O'Dea AP, Nye L, Sharma P, Wagner JL. Reducing Breast Cancer-Related Lymphedema (BCRL) Through Prospective Surveillance Monitoring Using Bioimpedance Spectroscopy (BIS) and Patient Directed Self-Interventions. Ann Surg Oncol. 2018 Oct;25(10):2948-2952. doi: 10.1245/s10434-018-6601-8. Epub 2018 Jul 9. PubMed 29987599 ↗

Related links

Individual participant data

Plan to share: No

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Oct 2026; primary completion for Oct 2031, 60 months later.

Of 1,070 non-industry phase 2 interventional studies under Breast Neoplasms, half reached primary completion within 56 months of starting (the median), counting those still running; a quarter within 34 and three quarters within 89. This study's planned 60 months is close to that.

Counting every sponsor, half of 1,302 studies reached it within 51 months; a quarter within 30 and three quarters within 83.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 16, 2026: start Jul 2026 → Oct 2026, primary completion Jul 2031 → Oct 2031 and completion Jul 2031 → Oct 2031.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
May 29, 2026
First posted
Jun 11, 2026
StartEst.
Oct 2026was Jul 2026
Primary completionEst.
Oct 2031was Jul 2031
CompletionEst.
Oct 2031was Jul 2031
Last update
Oct 16, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Start date
Jul 2026→Oct 2026
Oct 16, 2026
Primary completion
Jul 2031→Oct 2031
Oct 16, 2026
Study completion
Jul 2031→Oct 2031
Oct 16, 2026
Eligibility
1 inclusion criterion edited, 3 removed
What changed in the criteria
Inclusion criteria
  • RemovedPatients stage T1-3 cN1 (prior to start of neoadjuvant chemotherapy) and pN2-3 breast cancer based on number of positive nodes on final surgical pathology.
  • RemovedA minimum of 1 sentinel node must be identified and excised by the surgeon. Patients who do not have an identifiable sentinel lymph node will not proceed to omission of ALND.
  • RemovedPatients that have a pathologic complete response (pCR) in the breast and axilla can be considered for discussion at the Breast Multidisciplinary Tumor Conference for omission of radiation. Note: Isolated tumor cells (metastases less than or equal to 0.2 mm) will be treated as node negative disease (N0i+).
  • EditedFemales of childbearing potential must have a negative serum pregnancy at daytest performed - according to institutional standard of surgery in pre-operative holdingcare prior to initiating treatmentsurgery.
Oct 16, 2026
Show all 1 update
  1. Oct 16, 2026
    Start date Jul 2026→Oct 2026
    Primary completion Jul 2031→Oct 2031
    Study completion Jul 2031→Oct 2031
    Eligibility 1 inclusion criterion edited, 3 removed
    What changed in the criteria
    Inclusion criteria
    • RemovedPatients stage T1-3 cN1 (prior to start of neoadjuvant chemotherapy) and pN2-3 breast cancer based on number of positive nodes on final surgical pathology.
    • RemovedA minimum of 1 sentinel node must be identified and excised by the surgeon. Patients who do not have an identifiable sentinel lymph node will not proceed to omission of ALND.
    • RemovedPatients that have a pathologic complete response (pCR) in the breast and axilla can be considered for discussion at the Breast Multidisciplinary Tumor Conference for omission of radiation. Note: Isolated tumor cells (metastases less than or equal to 0.2 mm) will be treated as node negative disease (N0i+).
    • EditedFemales of childbearing potential must have a negative serum pregnancy at daytest performed - according to institutional standard of surgery in pre-operative holdingcare prior to initiating treatmentsurgery.
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07643584
Responsible party
Jamie Wagner, D.O. (Professor, University of Kansas Medical Center) — Principal investigator
First posted
Jun 11, 2026
Start date
Oct 2026 (estimated)
Primary completion
Oct 2031 (estimated)
Completion
Oct 2031 (estimated)
Last update
Oct 16, 2026

Study contacts

KUCC Navigation
Contact
kucc_navigation@kumc.edu
(913) 588-3671
Jamie Wagner, D.O.
principal investigator · The University of Kansas Cancer Center

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion